Cell Cycle Deregulation in Breast Cancer: Insurmountable Chemoresistance or Achilles’ Heel?

  • Laura Lambert
  • Khandan Keyomarsi
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 608)


Deregulation of the G1 cyclin, cyclin E, has been shown to be both the most powerful predictor of prognosis in early stage breast cancer as well as a significant determinant of tumor aggressiveness.1,2 It may also contribute to treatment failure due to chemoresistance. Because some form of cell cycle deregulation is present in all malignant cells,3 increasing understanding of these processes is starting to provide new opportunities to overcome the cells’ resistance mechanisms.

One particular form of cyclin E deregulation, the generation of hyperactive low molecular weight isoforms, is especially intriguing. Because only tumor cells contain the machinery necessary to generate these isoforms,4 they not only provide a mechanism of targeting critical cell cycle events, but their presence may also provide both a means of increased specificity for targeting malignant cells, as well as an objective measure of response.

This review describes the mechanisms of resistance to commonly used systemic therapies for the treatment of breast cancer, with particular respect to the role of the cell cycle. The mechanisms and effects of the deregulation of cyclin E in breast cancer are reviewed and novel approaches to circumventing chemoresistance through abrogation of the malignant cell cycle are proposed.


Breast Cancer Clin Oncol Cell Lung Cancer Cell Line Cell Cycle Deregulation Dihydrofolate Reductase Gene 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Keyomarsi K, O’Leary N, Molnar G et al. Cyclin E, a potential prognostic marker for breast cancer. Cancer Res 1994; 54(2):380–385.PubMedGoogle Scholar
  2. 2.
    Keyomarsi K, Tucker SL, Buchholz TA et al. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002; 347(20):1566–1575.PubMedCrossRefGoogle Scholar
  3. 3.
    Pardee AB. G1 events and regulation of cell proliferation. Science 1989; 246(4930):603–608.PubMedCrossRefGoogle Scholar
  4. 4.
    Porter DC, Zhang N, Danes C et al. Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms. Mol Cell Biol 2001; 21(18):6254–6269.PubMedCrossRefGoogle Scholar
  5. 5.
    Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 1998; 351(9114):1451–1467.CrossRefGoogle Scholar
  6. 6.
    Early Breast Cancer Trialists’ Collaborative Group. Polychemotherapy for early breast cancer: An overview of the randomised trials. Lancet 1998; 352(9132):930–942.CrossRefGoogle Scholar
  7. 7.
    Berns K, Hijmans EM, Bernards R. Repression of c-Myc responsive genes in cycling cells causes G1 arrest through reduction of cyclin E/CDK2 kinase activity. Oncogene 1997; 15(11):1347–1356.PubMedCrossRefGoogle Scholar
  8. 8.
    Berns K, Martins C, Dannenberg JH et al. p27kip1-independent cell cycle regulation by MYC. Oncogene 2000; 19(42):4822–4827.PubMedCrossRefGoogle Scholar
  9. 9.
    Beier R, Burgin A, Kiermaier A et al. Induction of cyclin E-cdk2 kinase activity, E2F-dependent transcription and cell growth by Myc are genetically separable events. Embo J 2000; 19(21):5813–5823.PubMedCrossRefGoogle Scholar
  10. 10.
    Roussel MF, Theodoras AM, Pagano M et al. Rescue of defective mitogenic signaling by D-type cyclins. Proc Natl Acad Sci USA 1995; 92(15):6837–6841.PubMedCrossRefGoogle Scholar
  11. 11.
    Leone G, DeGregori J, Sears R et al. Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F. Nature 1997; 387(6631):422–426.PubMedCrossRefGoogle Scholar
  12. 12.
    Santoni-Rugiu E, Falck J, Mailand N et al. Involvement of Myc activity in a G(1)/S-promoting mechanism parallel to the pRb/E2F pathway. Mol Cell Biol 2000; 20(10):3497–3509.PubMedCrossRefGoogle Scholar
  13. 13.
    Bartek J, Bartkova J, Lukas J. The retinoblastoma protein pathway and the restriction point. Curr Opin Cell Biol 1996; 8(6):805–814.Google Scholar
  14. 14.
    Sherr CJ, Roberts JM. CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev 1999; 13(12):1501–1512.PubMedCrossRefGoogle Scholar
  15. 15.
    Muller-Tidow C, Metzger R, Kugler K et al. Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage nonsmall cell lung cancer. Cancer Res 2001; 61(2):647–653.PubMedGoogle Scholar
  16. 16.
    Porter PL, Malone KE, Heagerty PJ et al. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997; 3(2):222–225.PubMedCrossRefGoogle Scholar
  17. 17.
    Richter J, Wagner U, Konomen J et al. High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am J Pathol 2000; 157(3):787–794.PubMedGoogle Scholar
  18. 18.
    Sui L, Dong Y, Ohno M et al. Implication of malignancy and prognosis of p27(kip1), Cyclin E, and Cdk2 expression in epithelial ovarian tumors. Gynecol Oncol 2001; 83(1):56–63.PubMedCrossRefGoogle Scholar
  19. 19.
    Gros P, Ben Neriah YB, Croop JM et al. Isolation and expression of a complementary DNA that confers multidrug resitance. Nature 1986; 323(6090):728–731.PubMedCrossRefGoogle Scholar
  20. 20.
    Koike K, Kawabe T, Tanaka T et al. A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. Cancer Res 1997; 57(24):5475–5479.PubMedGoogle Scholar
  21. 21.
    Cole SP, Chanda ER, Dicke FP et al. Non P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: Evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II. Cancer Res 1991; 51(13):3345–3352./PubMedGoogle Scholar
  22. 22.
    DeVore RF, Corbett AH, Osheroff N. Phosphorylation of topoisomerase II by casein kinase II and protein kinase C: Effects on enzyme-mediated DNA clevage/religation and sensitivity to the antineoplastic drugs etoposide and 4′-(9-acridinylamino)methane-sulfon-m-anisidide. Cancer Res 1992; 52(8):2156–2161.PubMedGoogle Scholar
  23. 23.
    Takano H, Kohno K, Ono M et al. Increased phosphorylation of DNA topisomerase II in etoposide-resistant mutants of human cancer KB cells. Cancer Res 1991; 51(15):3951–3957.PubMedGoogle Scholar
  24. 24.
    Feldhoff PW, Mirski SE, Cole SP et al. Altered subcellular distribution of topoisomerase II alpha in a drug-resistant human small cell lung cancer cell line. Cancer Res 1994; 54(3):756–762.PubMedGoogle Scholar
  25. 25.
    Mirski SE, Cole SP. Cytoplasmic localization of a mutant M(r) 160,000 topoisomerase II alpha is associated with the loss of putative bipartite nuclear localization signals in a drug resistant human lung cancer cell line. Cancer Res 1995; 55(10):2129–2134.PubMedGoogle Scholar
  26. 26.
    Harker WG, Slade DL, Parr RL et al. Sclective use of an alternative stop codon and polyadenylation signal within intron sequences leads to a truncated topoisomerase II alpha messenger RNA and protein in human HL-60 leukemia cells selected for resistance to mitoxantrone. Cancer Res 1995; 55(21):4962–4971.PubMedGoogle Scholar
  27. 27.
    Wessel I, Jensen PB, Falck J et al. Loss of amino acids 1490 Lys-Ser-Lys1492 in the COOH-terminal region of topoisomerase IIalpha inhuman small cell lung cencer cells selected for resistance to etoposide results in an extranuclear enzyme localization. Cancer Res 1997; 57(20):4451–4454.PubMedGoogle Scholar
  28. 28.
    Rubin E, Halt W. Anthracyclines and DNA Intercalators/Epipodophyllotoxins/Camptothecins/DNA Topoisomerases. In: Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, Frei E, eds. Cancer Medicine 6. Vol. 1. Hamilton: BC Decker, 2003:783.Google Scholar
  29. 29.
    Fenselau C, Kan MN, Rao SS et al. Identification of aldophosphamide as a metabolite of cyclophosphamide in vitro and in vivo in humans. Cancer Res 1977; 37(8 Pt 1):2538–2543.PubMedGoogle Scholar
  30. 30.
    Colvin M. Alkylating agents and platinum antitumor compounds. In: Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, Frei E, eds. Cancer Medicine 6. Vol. 1. Hamilton: BC Decker, 2003:762.Google Scholar
  31. 31.
    Colvin M, Russo JE, Hilton J et al. Enzymatic mechanisms of resistance to alkylating agents in tumor cells and normal tissues. Adv Enzyme Regul 1988; 27:211–221.PubMedCrossRefGoogle Scholar
  32. 32.
    Hilton J. Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210 leukemia. Cancer Res 1984; 44(11):5156–5160.PubMedGoogle Scholar
  33. 33.
    Koelling TM, Yeager AM, Hilton J et al. Development and characterization of a cyclophosphamide-resistant subline of acute myeloid leukemia in the Lewis x Brown Norway hybrid rat. Blood 1990; 76(6):1209–1213.PubMedGoogle Scholar
  34. 34.
    Parsons PG, Lean J, Kable EP et al. Relationship between resistanace to cross-linking agents and glutathione metabolism, aldehyde dehydrogenase isozymes and adenovirus replication in human tumour cell lines. Biochem Pharmacol 1990; 40(12):2641–2649.PubMedCrossRefGoogle Scholar
  35. 35.
    Rekha GK, Sreerama L, Sladek NE. Intrinsic cellular resistance to oxazaphosphorines exhibited by a human colon carcinoma cell line expressing relatively large amounts of a class-3 aldehyde dehydrogenase. Biochem Pharmacol 1994; 48(10):1943–1952.PubMedCrossRefGoogle Scholar
  36. 36.
    Sreerama L, Sladek NE. Identification of a methylcholanthrene-induced aldehyde dehydrogenase in a human breast adenocarcinoma cell line exhibiting oxazaphosphorine-specific acquired resistance. Cancer Res 1994; 54(8):2176–2185.PubMedGoogle Scholar
  37. 37.
    Buller AL, Clapper ML, Tew KD. Glutathione S-transferase in nitrogen mustard-resistant and-sensitive cell lines. Mol Pharmacol 1987; 31(6):575–578.PubMedGoogle Scholar
  38. 38.
    Nakagawa K, Saijo N, Tsuchida S et al. Glutathione-S-transferase pi as a determinant of drug resistance in transfectant cell lines. J Biol Chem 1990; 265(8):4296–4301.PubMedGoogle Scholar
  39. 39.
    Pallante SL, Lisek CA, Dulik DM et al. Glutathione conjugates. Immobilized enzyme synthesis and characterization by fast atom bombardment mass spectrometry. Drug Metab Dispos 1986; 1493):313–318.PubMedGoogle Scholar
  40. 40.
    Puchalski RB, Fahl WE. Expression of recombinant glutathione Sptransferase pi, Ya, or Yb1 confers resistance to alkylating agents. Proc Natl Acd Sci USA 1990; 87(7):2443–2447.CrossRefGoogle Scholar
  41. 41.
    Tew KD, Bomber AM, Hoffman SJ. Ethacrynic acid and piriprost as enhancers of cytotoxicity in drug resistant and sensitive cell lines. Cancer Res 1988; 48(13):3622–3625.PubMedGoogle Scholar
  42. 42.
    O’Connor PM, Ferris DK, White GA et al. Relationships between cdc2 kinase, DNA cross-linking, and cell cycle perturbations induced by nitrogen mustard. Cell Growth Differ 1992; 3(1):43–52.PubMedGoogle Scholar
  43. 43.
    Mulkins MA, Heidelberger C. Biochemical characterization of fluoropyrimidine-resistant murine leukemic cell lines. Cancer Res 1982; 42(3):965–973.PubMedGoogle Scholar
  44. 44.
    Mulkins MA, Heidelberger C. Isolation of fluoropyrimidine-resistant murine leukemic cell lines by one-step mutation and selection. Cancer Res 1982; 42(3):956–964.PubMedGoogle Scholar
  45. 45.
    Berger SH, Hakala MT. Relationship of dUMP and free FdUMP pools to inhibition of thymidylate synthase by 5-fluorouracil. Mol Pharmacol 1984; 25(2):303–309.PubMedGoogle Scholar
  46. 46.
    Houghton JA, Houghton PJ. Elucidation of pathways of 5-fluorouracil metabolism in exnografts of human colorectal adenocarcinoma. Eur J Cancer Clin Oncol 1983; 19(6):807–815.PubMedCrossRefGoogle Scholar
  47. 47.
    Kufe DW, Major PP, Egan EM et al. 5-Fluoro-2′-deoxyuridine incorporation in L1210 DNA. J Biol Chem 1981; 256(17):8885–8888.PubMedGoogle Scholar
  48. 48.
    Ingraham HA, Tseng BY, Goulian M. Mechanism for exclusion of 5-fluorouracil from DNA. Cancer Res 1980; 40(4):998–1001.PubMedGoogle Scholar
  49. 49.
    Morikawa K, Fan D, Denkins YM et al. Mechanisms of combined effects of gamma-interferon and 5-fluorouracil on human colon cancers implanted into nude mice. Cancer Res 1989; 49(4):799–805.PubMedGoogle Scholar
  50. 50.
    Jiang W, Lu Z, He Y et al. Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: Implication in 5-fluorouracil-based chemotherapy. Clin Cancer Res 1997; 3(3):395–399.PubMedGoogle Scholar
  51. 51.
    Etienne MC, Cheradame S, Fischel JL et al. Response to fluorouracil therapy in cancer patients: The role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 1995; 13(7):1663–1670.PubMedGoogle Scholar
  52. 52.
    Bapat AR, Zarow C, Danenberg PV. Human leukemic cells resistant to 5-fluoro-2′-deoxyuridine contain a thymidylate synthetase with lower affinity for nucleotides. J Biol Chem 1983; 258(7):4130–4136.PubMedGoogle Scholar
  53. 53.
    Berger SH, Jenh CH, Johnson LF et al. Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells. Mol Pharmacol 1985; 28(5):461–467.PubMedGoogle Scholar
  54. 54.
    Aschele C, Sobrero A, Faderan MA et al. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res 1992; 52(7):1855–1864.PubMedGoogle Scholar
  55. 55.
    Pizzorno G, Handschumacher RE. Effect of clinically modeled regimens on the growth response and development of resistance in human colon carcinoma cell lines. Biochem Pharmacol 1995; 49(4):559–565.PubMedCrossRefGoogle Scholar
  56. 56.
    Sobrero AF, Aschele C, Guglielmi AP et al. Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells. J Natl Cancer Inst 1993; 85(23):1937–1944.PubMedCrossRefGoogle Scholar
  57. 57.
    Pizzorno G, Diasio R, Cheng Y. Pyrimidine and Purine Antimetabolites. In Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, Frei E, eds. Cancer Medicine 6. Vol. 1. Hamilton: BC Decker, 2003:748.Google Scholar
  58. 58.
    Curt GA, Jolivet J, Carney DN et al. Determinants of the sensitivity of human small-cell lung cancer cell lines to methotrexate. J Clin Invest 1985; 76(4):1323–1329.PubMedCrossRefGoogle Scholar
  59. 59.
    Li WW, Waltham M, Tong W et al. Increased activity of gamma-glutamyl hydrolase in human sarcoma cell lines: A novel mechanism of intrinsic resistance to methotrexate (MTX). Adv Exp Med Biol 1993; 338:635–638.PubMedGoogle Scholar
  60. 60.
    Longo GS, Gorlick R, Tong WP et al. Disparate affinities of antifolates for folylpolyglutamate synthetase from human leukemia cells. Blood 1997; 90(3):1241–1245.PubMedGoogle Scholar
  61. 61.
    Li WW, Lin JT, Tong WP et al. Mechanisms of natural resistance to antifolates in human soft tissue sarcomas. Cancer Res 1992; 52(6):1434–1438.PubMedGoogle Scholar
  62. 62.
    Longo GS, Gorlick R, Tong WP et al. gamma-Glutamyl hydrolase and folylpolyglutamate synthetase activities predict polyglutamylation of methotrexate in acute leukemias. Oncol Res 1997; 9(5):259–263.PubMedGoogle Scholar
  63. 63.
    Guo W, Healey JH, Meyers PA et al. Mechanisms of methotrexate resistance in osteosarcoma. Clin Cancer Res 1999; 5(3):621–627.PubMedGoogle Scholar
  64. 64.
    Zhao R, Assaraf YG, Goldman ID. A mutated murine reduced folate carrier (RFC1) with increased affinity for folic acid, decreased affinity for methotrexate, and an obligatory anion requirement for transport function. J Biol Chem 1998; 273(30):19065–19071.PubMedCrossRefGoogle Scholar
  65. 65.
    Li W, Fan J, Hochhauser D et al. Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines. Proc Natl Acad Sci USA 1995; 92(22):10436–10440.PubMedCrossRefGoogle Scholar
  66. 66.
    Li W, Fan J, Banerjee D et al. Overexpression of p21(waf1) decreases G2-M arrest and apoptosis induced by paclitaxel in human sarcoma cells lacking both p53 and functional Rb protein. Mol Pharmacol 1999; 55(6):1088–1093.PubMedGoogle Scholar
  67. 67.
    Fan J, Bertino JR. Functional roles of E2F in cell cycle regulation. Oncogene 1997; 14(10):1191–1200.PubMedCrossRefGoogle Scholar
  68. 68.
    Alt FW, Kellems RE, Bertino JR et al. Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells 1978. Biotechnology 1992; 24:397–410.PubMedGoogle Scholar
  69. 69.
    Carman MD, Schornagel JH, Rivest RS et al. Resistance to methotrexate due to gene amplification in a patient with acute leukemia. J Clin Oncol 1984; 2(1):16–20.PubMedGoogle Scholar
  70. 70.
    Cowan KH, Goldsmith ME, Levine RM et al. Dihydrofolate reductase gene amplification and possible rearrangement in estrogen-responsive methotrexate-resistant human breast cancer cells. J Biol Chem 1982; 257(24):15079–15086.PubMedGoogle Scholar
  71. 71.
    Curt GA, Carney DN, Cowan KH et al. Unstable methotrexate resistance in human small-cell carcinoma associated with double minute chromosomes. N Engl J Med 1983; 308(4):199–202.PubMedGoogle Scholar
  72. 72.
    Fischer GA. Increased levels of folic acid reductase as a mechanism of resistance to amethopterin in leukemic cells. Biochem Pharmacol 1961; 7:75–77.PubMedCrossRefGoogle Scholar
  73. 73.
    Horns Jr RC, Dower WJ, Schimke RT. Gene amplification in a leukemic patient treated with methotrexate. J Clin Oncol 1984; 2(1):2–7.PubMedGoogle Scholar
  74. 74.
    Srimatkandada S, Medina WD, Cashmore AR et al. Amplification and organization of dihydrofolate reductase genes in a human leukemic cell line, K-562, resistant to methotrexate. Biochemistry 1983; 22(25):5774–5781.PubMedCrossRefGoogle Scholar
  75. 75.
    Dedhar S, Hartley D, Fitz-Gibbons D et al. Heterogeneity in the specific activity and methotrexate sensitivity of dihydrofolate reductase from blast cells of acute myelogenous leukemia patients. J Clin Oncol 1985; 3(11):1545–1552.PubMedGoogle Scholar
  76. 76.
    Domin BA, Cheng YC, Hakala MT. Properties of dihydrofolate reductase from a methotrexate-resistant subline of human KB cells and comparison with enzyme from KB parent cells and mouse S180 AT/3000 cells. Mol Pharmacol 1982; 21(1):231–238.PubMedGoogle Scholar
  77. 77.
    Flintoff WF, Essani K. Methotrexate-resistant Chinese hamster ovary cells contain a dihydrofolate reductase with an altered affinity for methotrexate. Biochemistry 1980; 19(18):4321–4327.PubMedCrossRefGoogle Scholar
  78. 78.
    Goldie JH, Dedhar S, Krystal G. Properties of a methotrexate-insensitive variant of dihydrofolate reductase derived from methotrexate-resistant L5178Y cells. J Biol Chem 1981; 256(22):11629–11635.PubMedGoogle Scholar
  79. 79.
    Melera PW, Davide JP, Oen H. Antifolate-resistant Chinese hamster cells. Molecular basis for the biochemical and structural heterogeneity among dihydrofolate reductases produced by drug-sensitive and drug-resistant cell lines. J Biol Chem 1988; 263(4):1978–1990.PubMedGoogle Scholar
  80. 80.
    Gorlick R, Goker E, Trippett T et al. Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. Blood 1997; 89(3):1013–1018.PubMedGoogle Scholar
  81. 81.
    Rowinsky E. Microtubule-targeting natural products. In: Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, Frei E, eds. Cancer Medicine 6. Vol 1. Hamilton: BC Decker, 2003:799.Google Scholar
  82. 82.
    Jordan MA, Toso RJ, Thrower D et al. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 1993; 90(20):9552–9556.PubMedCrossRefGoogle Scholar
  83. 83.
    Dumontet C, Sikic BI. Mechanisms of action of and resistance to antitubulin agents: Microtubule dynamics, drug transport, and cell death. J Clin Oncol 1999; 17(3):1061–1070.PubMedGoogle Scholar
  84. 84.
    Torres K, Horwitz SB. Mechanisms of Taxol-induced cell death are concentration dependent. Cancer Res 1998; 58(16):3620–3626.PubMedGoogle Scholar
  85. 85.
    Wang LG, Liu XM, Kreis W et al. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: A review. Cancer Chemother Pharmacol 1999; 44(5):355–361.PubMedCrossRefGoogle Scholar
  86. 86.
    Huisman C, Ferreira CG, Broker LE et al. Paclitaxel triggers cell death primarily via caspase-independent routes in the nonsmall cell lung cancer cell line NCI-H460. Clin Cancer Res 2002; 8(2):596–606.PubMedGoogle Scholar
  87. 87.
    Horwitz SB, Cohen D, Rao S et al. Taxol: Mechanisms of action and resistance. J Natl Cancer Inst Monorg 1993; (15):55–61.Google Scholar
  88. 88.
    Cabral F, Wible L, Brenner S et al. Taxol-requiring mutant of Chinese hamster ovary cells with impaired mitotic spindle assembly. J Cell Biol 1983; 97(1):30–39.PubMedCrossRefGoogle Scholar
  89. 89.
    Cabral FR. Isolation of Chinese hamster ovary cell mutants requiring the continuous presence of taxol for cell division. J Cell Biol 1983; 97(1):22–29.PubMedCrossRefGoogle Scholar
  90. 90.
    Kavallaris M, Kuo DY, Burkhart CA et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 1997; 100(5):1282–1293.PubMedCrossRefGoogle Scholar
  91. 91.
    Nicoletti MI, Valoti G, Giannakakou P et al. Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: Correlation with sensitivity to microtubule active agents. Clin Cancer Res 2001; 7(9):2912–2922.PubMedGoogle Scholar
  92. 92.
    Ranganathan S, Benetatos CA, Colarusso PJ et al. Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells. Br J Cancer 1998; 77(4):562–566.PubMedGoogle Scholar
  93. 93.
    Dubik D, Dembinski TC, Shiu RP. Stimulation of c-myc oncogene expression associated with estrogen-induced proliferation of human breast cancer cells. Cancer Res 1987; 47(24) Pt 1): 6517–6521.PubMedGoogle Scholar
  94. 94.
    Dubik D, Shiu RP. Mechanism of estrogen activation of c-myc oncogene expression. Oncogene 1992; 7(8):1587–1594.PubMedGoogle Scholar
  95. 95.
    Murphy LJ, Murphy LC, Friesen HG. Estrogen induction of N-myc and c-myc proto-oncogene expression in the rat uterus. Endocrinology 1987; 120(5):1882–1888.PubMedCrossRefGoogle Scholar
  96. 96.
    Prall OW, Sarcevic B, Musgrove EA et al. Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2. J Biol Chem 1997; 272(16):10882–10894.PubMedCrossRefGoogle Scholar
  97. 97.
    Altucci L, Addeo R, Cicatiello L et al. 17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene 1996; 12(11):2315–2324.PubMedGoogle Scholar
  98. 98.
    Planas-Silva MD, Weinberg RA. Estrogen-dependent cyclin E-cdk2 activation through p21 redistribution. Mol Cell Biol 1997; 17(7):4059–4069.PubMedGoogle Scholar
  99. 99.
    Prall OW, Carroll JS, Sutherland RL. A low abundance pool of nascent p21WAF1/Cip1 is targeted by estrogen to activate cyclin E*Cdk2. J Biol Chem 2001; 276(48):45433–45442.PubMedCrossRefGoogle Scholar
  100. 100.
    Osborne CK, Shou J, Massarweh S et al. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res 2005; 11(2 Pt 2):865s–870s.PubMedGoogle Scholar
  101. 101.
    Razandi M, Alton G, Pedram A et al. Identification of a structural determinant necessary for the localization and function of estrogen receptor alpha at the plasma membrane. Mol Cell Biol 2003; 23(5):1633–1646.PubMedCrossRefGoogle Scholar
  102. 102.
    McKenna NJ, Lanz RB, O’Malley BW. Nuclear receptor coregulator: Cellular and molecular biology. Endocr Rev 1999; 20(3):321–344.PubMedCrossRefGoogle Scholar
  103. 103.
    Osborne CK, Zhao H, Fuqua SA. Selective estrogen receptor modulators: Structure, function, and clinical use. J Clin Oncol 2000; 18(17):3172–3186.PubMedGoogle Scholar
  104. 104.
    Parker MG. Steroid and related receptors. Curr Opin Cell Biol 1993; 5(3):499–504.PubMedCrossRefGoogle Scholar
  105. 105.
    Shou J, Massarweh S, Osborne CK et al. Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004; 96(12):926–935.PubMedCrossRefGoogle Scholar
  106. 106.
    Kato S, Endoh H, Masuhiro Y et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 1995; 270(5241):1491–1494.PubMedCrossRefGoogle Scholar
  107. 107.
    Font de Mora J, Brown M. AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol Cell Biol 2000; 20(14):5041–5047.PubMedCrossRefGoogle Scholar
  108. 108.
    Nicholson RI, McClelland RA, Robertson JF et al. Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr Relat Cancer 1999; 6(3):373–387.PubMedCrossRefGoogle Scholar
  109. 109.
    Osborne CK, Bardou V, Hopp TA et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003; 95(5):353–361.PubMedGoogle Scholar
  110. 110.
    Smith CL, Nawaz Z, O’Malley BW. Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol 1997; 11(6):657–666.PubMedCrossRefGoogle Scholar
  111. 111.
    Buzdar A, Harvey H. Aromatase Inhibitors. In: Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, Frei E, eds. Cancer Medicine 6. Vol 1. Hamilton: BC Decker, 2003;947.Google Scholar
  112. 112.
    Ellis MJ, Coop A, Singh B et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 2001; 19(18):3808–3816.PubMedGoogle Scholar
  113. 113.
    Howell A, Cuzick J, Baum M et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005; 365(9453):60–62.PubMedCrossRefGoogle Scholar
  114. 114.
    Buzdar A, Harvey H. Aromatase Inhibitors. In Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, Frei E, eds. Cancer Medicine 6. Vol 1. Hamilton: BC Decker, 2003:957.Google Scholar
  115. 115.
    Yu D, Hung MC. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 2000; 19(53):6115–6121.PubMedCrossRefGoogle Scholar
  116. 116.
    Nagata Y, Lan KH, Zhou X et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004; 6(2):117–127.PubMedCrossRefGoogle Scholar
  117. 117.
    Dieras V, Fumoleau P, Romieu G et al. Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol 2004; 22(24):4958–4965.PubMedCrossRefGoogle Scholar
  118. 118.
    Buzdar AU, Singletary SE, Theriault RL et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 1999; 17(11):3412–3417.PubMedGoogle Scholar
  119. 119.
    Paridaens R, Dirix L, Lohrisch C et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 2003; 14(9):1391–1398.PubMedCrossRefGoogle Scholar
  120. 120.
    Nabholtz JM, Buzdar A, Pollak M et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000; 18(22):3758–3767.PubMedGoogle Scholar
  121. 121.
    Milla-Santos A, Milla L, Portella J et al. Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: A prospective, randomized, phase III study. Am J Clin Oncol 2003; 26(3):317–322.PubMedCrossRefGoogle Scholar
  122. 122.
    Mouridsen H, Gershanovich M, Sun Y et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003; 21(11):2101–2109.PubMedCrossRefGoogle Scholar
  123. 123.
    Eiermann W, Paepke S, Appfelstaedt J et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol 2001; 12(11):1527–1532.PubMedCrossRefGoogle Scholar
  124. 124.
    Bonneterre J, Thurlimann B, Robertson JF et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000; 18(22):3748–3757.PubMedGoogle Scholar
  125. 125.
    Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20(3):719–726.PubMedCrossRefGoogle Scholar
  126. 126.
    Norbury C, Nurse P. Animal cell cycles and their control. Annu Rev Biochem 1992; 61:441–470.PubMedCrossRefGoogle Scholar
  127. 127.
    Hartwell LH, Weinert TA. Checkpoints: Controls that ensure the order of cell cycle events. Science 1989; 246(4930):629–634.PubMedCrossRefGoogle Scholar
  128. 128.
    Pardee AB. A restriction point for control of normal animal cell proliferation. Proc Natl Acad Sci USA 1974; 71(4):1286–1290.PubMedCrossRefGoogle Scholar
  129. 129.
    Evans T, Rosenthal ET, Youngblom J et al. Cyclin: A protein specified by maternal mRNA in sea urchin eggs that is destroyed at each cleavage division. Cell 1983; 33(2):389–396.PubMedCrossRefGoogle Scholar
  130. 130.
    Pines J. Cyclins: Wheels within wheels. Cell Growth Differ 1991; 2(6):305–310.PubMedGoogle Scholar
  131. 131.
    Ohtsubo M, Theodoras AM, Schumacher J et al. Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol 1995; 15(5):2612–2624.PubMedGoogle Scholar
  132. 132.
    Keyomarsi K, Herliczek TW. The role of cyclin E in cell proliferation, development and cancer. Prog Cell Cycle Res 1997; 3:171–191.PubMedGoogle Scholar
  133. 133.
    Zhang HS, Gavin M, Dahiya A et al. Exit from G1 and S phase of the cell cycle is regulated by repressor complexes containing HDAC-Rb-hSWI/SNF and Rb-hSWI/SNF. Cell 2000; 101(1):79–89.PubMedCrossRefGoogle Scholar
  134. 134.
    Montagnoli A, Fiore F, Eytan E et al. Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev 1999; 13(9):1181–1189.PubMedCrossRefGoogle Scholar
  135. 135.
    Perez-Roger I, Kim SH, Griffiths B et al. Cyclins D1 and D2 mediate myc-induced proliferation via sequenstration of p27(Kip10 and p21(Cip1). Embo J 1999; 18(19):5310–5320.PubMedCrossRefGoogle Scholar
  136. 136.
    Alevizopoulos K, Vlach J, Hennecke S et al. Cyclin E and c-Myc promote cell proliferation in the presence of p16INK4a and of hypophosphorylated retinoblastoma family proteins. Embo J 1997; 16(17):5322–5333.PubMedCrossRefGoogle Scholar
  137. 137.
    Cassia R, Moreno-Bueno G, Rodriguez-Perales S et al. Cyclin E gene (CCNE) amplification and hCDC4 mutations in endometrial carcinoma. J Pathol 2003; 201(4):589–595.PubMedCrossRefGoogle Scholar
  138. 138.
    Schraml P, Bucher C, Bissig H et al. Cyclin E overexpression and amplification in human tumours. J Pathol 2003; 200(3):375–382.PubMedCrossRefGoogle Scholar
  139. 139.
    Strohmaier H, Spruck CH, Kaiser P et al. Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature 2001; 413(6853):316–322.PubMedCrossRefGoogle Scholar
  140. 140.
    Rajagopalan H, Jallepalli PV, Rago C et al. Inactivation of hCDC4 can cause chromosomal instability. Nature 2004; 428(6978):77–81.PubMedCrossRefGoogle Scholar
  141. 141.
    Bloom J, Pagano M. Deregulated degradation of the edk inhibitor p27 and malignant transformation. Semin Cancer Biol 2003; 13(1):41–47.PubMedCrossRefGoogle Scholar
  142. 142.
    Koepp DM, Schaefer LK, Ye X et al. Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science 2001; 294(5540):173–177.PubMedCrossRefGoogle Scholar
  143. 143.
    Harwell RM, Porter DC, Danes C et al. Processing of cyclin E differs between normal and tumor breast cells. Cancer Res 2000; 60(2):481–489.PubMedGoogle Scholar
  144. 144.
    Akli S, Zheng PJ, Multani AS et al. Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Res 2004; 64(9):3198–3208.PubMedCrossRefGoogle Scholar
  145. 145.
    Furstenthal L, Kaiser BK, Swanson C et al. Cyclin E uses Cdc6 as a chromatin-associated receptor required for DNA replication. J Cell Biol 2001; 152(6):1267–1278.PubMedCrossRefGoogle Scholar
  146. 146.
    Ma T, Van Tine BA, Wei Y et al. Cell cycle-regulated phosphorylation of p220(NPAT) by cyclin E/Cdk2 in Cajal bodies promotes histone gene transcription. Genes Dev 2000; 14(18):2298–2313.PubMedCrossRefGoogle Scholar
  147. 147.
    Zhao J, Kennedy BK, Lawrence BD et al. NPAT links cyclin E-Cdk2 to the regulation of replication-dependent histone gene transcription. Genes Dev 2000; 14(18):2283–2297.PubMedCrossRefGoogle Scholar
  148. 148.
    Fisk HA, Winey M. The mouse Mps1p-like kinase regulates centrosome duplication. Cell 2001; 106(1):95–104.PubMedCrossRefGoogle Scholar
  149. 149.
    Okuda M, Horn HF, Tarapore P et al. Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell 2000; 103(1):127–140.PubMedCrossRefGoogle Scholar
  150. 150.
    Shanahan F, Seghezzi W, Parry D et al. Cyclin E associates with BAF155 and BRG1, components of the mammalian SWI-SNF complex, and alters the ability of BRG1 to induce growth arrest. Mol Cell Biol 1999; 19(2):1460–1469.PubMedGoogle Scholar
  151. 151.
    Wang C, Chua K, Seghezzi W et al. Phosphorylation of spliceosomal protein SAP 155 coupled with splicing catalysis. Genes Dev 1998; 12(10):1409–1414.PubMedCrossRefGoogle Scholar
  152. 152.
    Seghezzi W, Chua K, Shanahan F et al. Cyclin E associates with components of the premRNA splicing machinery in mammalian cells. Mol Cell Biol 1998; 18(8):4526–4536.PubMedGoogle Scholar
  153. 153.
    Hara E, Hall M, Peters G. Cdk2-dependent phosphorylation of Id2 modulates activity of E2A-related transcription factors. Embo J 1997; 16(2):332–342.PubMedCrossRefGoogle Scholar
  154. 154.
    Deed RW, Hara E, Atherton GT et al. Regulation of Id3 cell cycle function by Cdk-2-dependent phosphorylation. Mol Cell Biol 1997; 17(12):6815–6821.PubMedGoogle Scholar
  155. 155.
    Ohtsubo M, Roberts JM. Cyclin-dependent regulation of G1 in mammalian fibroblasts. Science 1993; 259(5103):1908–1912.PubMedCrossRefGoogle Scholar
  156. 156.
    Akli S, Keyomarsi K. Cyclin E and its low molecular weight forms in human cancer and as targets for cancer therapy. Cancer Biol Ther 2003; 2 (4 Suppl 1):S38–47.Google Scholar
  157. 157.
    Park JW. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res 2002; 4(3):95–99.PubMedCrossRefGoogle Scholar
  158. 158.
    Carlson BA, Dubay MM, Sausville EA et al. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res 1996; 56(13):2973–2978.PubMedGoogle Scholar
  159. 159.
    Losiewicz MD, Carlson BA, Kaur G et al. Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275. Biochem Biophys Res Commun 1994; 201(2):589–595.PubMedCrossRefGoogle Scholar
  160. 160.
    Gray NS, Wodicka L, Thunnissen AM et al. Exploiting chemical libraries, structure, and genomics in the search for kinase in hibitors. Science 1998; 281(5376):533–538.PubMedCrossRefGoogle Scholar
  161. 161.
    Senderowicz AM, Headlee D, Stinson SF et al. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 1998; 16(9):2986–2999.PubMedGoogle Scholar
  162. 162.
    Thomas JP, Tutsch KD, Cleary JF et al. Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol. Cancer Chemother Pharmacol 2002; 50(6):465–472.PubMedCrossRefGoogle Scholar
  163. 163.
    Schiller JH, Harrington D, Belani CP. et al. Comparison of four chemotherapy regimens for advanced nonsmall-cell lung cancer. N Engl J Med 2002; 346(2):92–98.PubMedCrossRefGoogle Scholar
  164. 164.
    Shapiro GI, Supko JG, Patterson A et al. A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV nonsmall cell lung cancer. Clin Cancer Res 2001; 7(6):1590–1599.PubMedGoogle Scholar
  165. 165.
    Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with nonsmall cell lung cancer: A randomized trial. Jama 2003; 290(16):2149–2158.PubMedCrossRefGoogle Scholar
  166. 166.
    Meijer L, Borgne A, Mulner O et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 1997; 243(1–2):527–536.PubMedCrossRefGoogle Scholar
  167. 167.
    McClue SJ, Blake D, Clarke R et al. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer 2002;102(5):463–468.PubMedCrossRefGoogle Scholar
  168. 168.
    Benson C, White J, Twelves C et al. A phase I trial of the oral cyclin dependent kinase inhibitor CYC202 in patients with advanced malignancy. Chicago, Il: Paper presented at: Annual Meeting of the American Society of Clinical Oncology, 2003.Google Scholar
  169. 169.
    Pierga J, Faiver S, Vera K. A phase I and pharmacokinetic (PK) trial of CYC202, a novel oral cyclin-dependent kinase (CDK) inhibitor, in patients (pts) with advanced solid tumors. Chicago, Il: Paper presented at: Annual Meeting of the American Society of Clinical Oncology, 2003.Google Scholar
  170. 170.
    Kim KS, Kimball SD, Misra RN et al. Discovery of aminothiazole inhibitors of cyclin-dependent kinase 2: Synthesis, X-ray crystallographic analysis, and biological activities. J Med Chem 2002; 45(18):3905–3927.PubMedCrossRefGoogle Scholar
  171. 171.
    Shapiro G, Lewis N, Bai S et al. A phase I study to determine the safety and pharmacokinetics (PK) of BMS-387032. Chicago, Il: Paper presented at: Annual Meeting of the American Society of Clinical Oncology, 2003.Google Scholar
  172. 172.
    McCormick J, Gadgeel M, Helmke W et al. Phase I study of BMS-387032, a cyclin dependent kinase (CDK) 2 inhibitor. Chicago, Il: Paper presented at: Annual Meeting of the American Society of Clinical Oncology, 2003.Google Scholar
  173. 173.
    Jones S, Burris H, Kies M et al. A phase I study to determine the safety and pharmacokinetics (PK) of BMS-387032 given intravenously every three weeks in patients with metastatic refractory solid tumors. Chicago: Il: Paper presented at: Annual Meeting of the American Society of Clinical Oncology, 2003.Google Scholar
  174. 174.
    Akinaga S, Nomura K, Gomi K et al. Effect of UCN-01, a selective inhibitor of protein kinase C, on the cell-cycle distribution of human epidermoid carcinoma, A431 cells. Cancer Chemother Pharmacol 1994; 33(4):273–280.PubMedCrossRefGoogle Scholar
  175. 175.
    Akiyama T, Yoshida T, Tsujita T et al. G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells. Cancer Res 1997; 57(8):1495–1501.PubMedGoogle Scholar
  176. 176.
    Akiyama T, Shimizu M, Okabe M et al. Differential effects of UCN-01, staurosporine and CGP 41 251 on cell cycle progression and CDC2/cyclin B1 regulation in A431 cells synchronized at M phase by nocodazole. Anticancer Drugs 1999; 10(1):67–78.PubMedCrossRefGoogle Scholar
  177. 177.
    Chen X, Lowe M, Keyomarsi K. UCN-01-mediated G1 arrest in normal but not tumor breast cells is pRb-dependent and p53-independent. Oncogene 1999; 18(41):5691–5702.CrossRefGoogle Scholar
  178. 178.
    Kawakami K, Futami H, Takahara J et al. UCN-01, 7-hydroxyl-staurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line. Biochem Biophys Res Commun 1999; 219(3):778–783.CrossRefGoogle Scholar
  179. 179.
    Seynaeve CM, Stetler-Stevenson M, Sebers S et al. Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells. Cancer Res 1993; 53(9):2081–2086.PubMedGoogle Scholar
  180. 180.
    Shimizu E, Zhao MR, Nakanishi H et al. Differing effects of staurosporine and UCN-01 on RB protein phosphorylation and expression of lung cancer cell lines. Oncology 1996; 53(6):494–504.PubMedCrossRefGoogle Scholar
  181. 181.
    Usuda J, Saijo N, Fukuoka K et al. Molecular determinants of UCN-01-induced growth inhibition in human lung cancer cells. Int J Cancer 2000; 85(2):275–280.PubMedGoogle Scholar
  182. 182.
    Wang Q, Fan S, Eastman A et al. UCN-01: A potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst 1996; 88(14):956–965.PubMedCrossRefGoogle Scholar
  183. 183.
    Busby EC, Leistritz DF, Abraham RT et al. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res 2000; 60(8):2108–2112.PubMedGoogle Scholar
  184. 184.
    Graves PR, Yu L, Schwarz JK et al. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem 2000; 275(8):5600–5605.PubMedCrossRefGoogle Scholar
  185. 185.
    Sarkaria JN, Busby EC, Tibbetts RS et al. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res 1999; 59(17):4375–4382.PubMedGoogle Scholar
  186. 186.
    Sato S, Fujita N, Tsuruo T. Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). Oncogene 2002; 21(11):1727–1738.PubMedCrossRefGoogle Scholar
  187. 187.
    Testa JR, Bellacosa A. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA 2001; 98(20):10983–10985.PubMedCrossRefGoogle Scholar
  188. 188.
    Sausville EA, Arbuck SG, Messmann R et al. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. J Clin Oncol 2001; 19(8):2319–2333.PubMedGoogle Scholar
  189. 189.
    Senderowicz A, Headlee D, Lush R et al. Phase I trial of infusional UCN-01, a novel protein kinase inhibitor, in patients with refractory neoplasms. Amsterdam, Holland: Paper presented at: 10th National Cancer Institute-European Organization fro Research on Treatment of Cancer Symposium, 1998.Google Scholar
  190. 190.
    Shao RG, Cao CX, Shimizu T et al. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res 1997; 57(18):4029–4035.PubMedGoogle Scholar
  191. 191.
    Jones CB, Clements MK, Wasi S et al. Enhancement of camptothecin-induced cytotoxicity with UCN-01 in breast cancer cells: Abrogation of S/G(2) arrest. Cancer Chemother Pharmacol 2000; 45(3):252–258.PubMedCrossRefGoogle Scholar
  192. 192.
    Hsueh CT, Kelsen D, Schwartz GK. UCN-01 suppresses thymidylate synthase gene expression and enhances 5-fluorouracil-induced apoptosis in a sequence-dependent manner. Clin Cancer Res 1998; 4(9):2201–2206.PubMedGoogle Scholar
  193. 193.
    Bunch RT, Eastman A. Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor. Clin Cancer Res 1996; 2(5):791–797.PubMedGoogle Scholar
  194. 194.
    Garcia HH, Brar GA, Nguyen DH et al. Indole-3-carbinol (I3C) inhibits cyclin-dependent kinase-2 function in human breast cancer cells by regulating the size distribution, associated cyclin E forms, and subcellular localization of the CDK2 protein complex. J Biol Chem 2005; 280(10):8756–8764.PubMedCrossRefGoogle Scholar
  195. 195.
    Chen X, Danes C, Lowe M et al. Activation of the estrogen-signaling pathway by p21(WAF1/CIP1) in estrogen receptor-negative breast cancer cells. J Natl Cancer Inst 2000; 92(17):1403–1413.PubMedCrossRefGoogle Scholar
  196. 196.
    Barboule N, Chadebech P, Baldin V et al. Involvement of p21 in mitotic exit after paclitaxel treatment in MCF-7 breast adenocarcinoma cell line. Oncogene 1997; 15(23):2867–2875.PubMedCrossRefGoogle Scholar
  197. 197.
    Yu D, Jing T, Liu B et al. Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. Mol Cell 1998; 2(5):581–591.PubMedCrossRefGoogle Scholar
  198. 198.
    Bacus SS, Yarden Y, Oren M et al. Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells. Oncogene 1996; 12(12):2535–2547.PubMedGoogle Scholar
  199. 199.
    Sugiyama K, Shimizu M, Akiyama T et al. Combined effect of navelbine with medroxyprogesterone acetate against human breast carcinoma MCF-7 cells in vitro. Br J Cancer 1998; 77(11):1737–1743.PubMedGoogle Scholar
  200. 200.
    Rao S, Porter DC, Chen X et al. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc natl Acad Sci USA 1999; 96(14):7797–7802.PubMedCrossRefGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2007

Authors and Affiliations

  1. 1.Departments of Surgical Oncology and Experimental Radiation Oncology at University of TexasMD Anderson Cancer CenterHoustonUSA

Personalised recommendations